Home / Resource Library / High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

Article discusses various molecular and cellular therapy options for treating CLL.